Comment on

• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Solomon BJ, et al. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Clinical Trial.
• First-line crizotinib in ALK-positive lung cancer.

  Tural D, Kilickap S. Tural D, et al. N Engl J Med. 2015 Feb 19;372(8):781. doi: 10.1056/NEJMc1415973. N Engl J Med. 2015. PMID: 25693022 No abstract available.
• First-line crizotinib in ALK-positive lung cancer.

  Alkan A, Köksoy EB, Utkan G. Alkan A, et al. N Engl J Med. 2015 Feb 19;372(8):781-2. doi: 10.1056/NEJMc1415973. N Engl J Med. 2015. PMID: 25693023 No abstract available.